NeoGenomics (NEO) stock declined over 10% after its 2026 financial forecast, including adjusted earnings per share and adjusted EBITDA, fell short of analyst expectations, overshadowing strong fourth-quarter revenue growth. The company reported a net loss of $108 million for full-year 2025, a 37% increase, and its stock has been highly volatile, down 13% since the start of 2026. This performance underscores the market’s negative reaction to the weaker outlook despite positive quarterly revenue figures.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses Expectations - News and Statistics
NeoGenomics (NEO) stock declined over 10% after its 2026 financial forecast, including adjusted earnings per share and adjusted EBITDA, fell short of analyst expectations, overshadowing strong fourth-quarter revenue growth. The company reported a net loss of $108 million for full-year 2025, a 37% increase, and its stock has been highly volatile, down 13% since the start of 2026. This performance underscores the market’s negative reaction to the weaker outlook despite positive quarterly revenue figures.